Navigation Links
For some diabetics, burden of care rivals complications of disease
Date:9/26/2007

Many patients with diabetes say that the inconvenience and discomfort of constant therapeutic vigilance, particularly multiple daily insulin injections, has as much impact on their quality of life as the burden of intermediate complications, researchers from the University of Chicago report in the October 2007 issue of Diabetes Care.

A typical diabetes patient takes many medications each day, including two or three different pills to control blood sugar levels, one or two to lower cholesterol, two or more to reduce blood pressure, a daily aspirin to prevent blood clots, plus diet and exercise. As the disease progresses, the drugs increase, often including insulin shots.

"The people who care for patients with a chronic disease like diabetes think about that disease and about preventing long-term complications," said study author Elbert Huang, MD, assistant professor of medicine at the University of Chicago. "The people who have a chronic disease think about their immediate lives, which includes the day-to-day costs and inconvenience of a multi-drug regimen. The consequences are often poor compliance, which means long-term complications, which will then require more medications."

Despite growing reliance on such complex multi-drug regimens, large proportions of patients with type-2 diabetes continue to have poorly controlled glucose (20%), blood pressure (33%) and cholesterol (40%).

"This tells us that we need to find better, more convenient ways to treat chronic illness," Huang said. "It is hard to convince some patients to invest their time and effort now in rigorous adherence to a complex regimen with no immediate reward, just the promise of better health years from now," Huang said.

"This certainly rings true to me," agreed diabetes specialist Louis Philipson, MD, PhD, professor of medicine at the University of Chicago, who was not part of the research team. "Some patients, if you judge by their behavior, would r
'/>"/>

Contact: John Easton
John.Easton@uchospitals.edu
773-702-6241
University of Chicago Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Burden of lung disease
2. Suggestions to reduce global heart disease burden
3. Poor Health of people in Central Goldfields Shire, reports The Victorian Burden of Disease
4. Study Finds ER Not Overburdened By Uninsured & Immigrants
5. Dementia Care Intervention Eases Burden for Families
6. America Sags Under Burden of Neurological Diseases
7. Increased Depression, Burden, Reported in Family Caregivers of ALS Patients
8. Refugees No Burden On Health System
9. Hospital Infections Like MRSA Affect The New Arrivals More
10. Rivals of the South Dakota Law Says No to Abortion
11. Coronary stent leads to complications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...ombining natural organic atoms with metal complexe...ed a new type of enzyme inhibitor capable of block... cancer development. , Based on studies in huma...eveloping new ways to treat cancer by dampening th...olled tumor growth. , Details of the study, to b...
(Date:5/15/2008)...ay 15 /PRNewswire-FirstCall/ -- Lung cancer patien...sions may fare better as a,result, according to da...C),clinical trial. Data from the trial, which invo... for injection), will be presented at the 44th Ann...cology (ASCO) in Chicago,Ill., May 30 -- June 3, ...
(Date:5/15/2008)...ity-control audit of community hospitals associate...gests that a partnership between a major academic ...are created, and community hospitals, where most c...uickly and effectively disseminating advances in c...d Comprehensive Cancer Center in Philadelphia, fir...
(Date:5/15/2008)...motherapy given in conjunction with cancer vaccine...ly improving the effectiveness of this promising t...earchers in the Duke Comprehensive Cancer Center. ...ls that suppress immune function and we speculated...used in conjunction with vaccines, which work by b...
Breaking Medicine News(10 mins):Health News:Novel enzyme inhibitor paves way for new cancer drug 2Health News:Novel enzyme inhibitor paves way for new cancer drug 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 2Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 4Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 5Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 6Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 7Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 2Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 3Health News:Chemotherapy might help cancer vaccines work 2
...arbor Hospital in Los Angeles seems to be lurching...s subjected to withering criticism in the media wh...And on Thursday the Los Angeles county officials w...ian state government that the license of the hospi...
... southern part of England register the lowest numb...n, the lowest levels of obesity and the longest l...s to the north - has the lowest life expectancy fo...ol was worst for women. Those in both cities liv...
...doublespeak of the Bush administration over WTC bo...ed people living in the neighborhood of the devas...s this famous sequence in Michael Moores Sicko, cu...at the front of a boat, surrounded by some of the ...
...s and top hotels are to go dark for an hour on Thu...for the fight against global warming and turns off...tels like the Ritz and key businesses have confirm...Lights Out" campaign from 9:00 pm to 10:00 pm (200...
Other Medicine News:Health News:California Government to Revoke License of LA Hospital 2Health News:Southern England Far Healthier Than the North 2Health News:WTC Neighborhood Residents Misled on Extent of Contamination 2
(Date:5/14/2008)... with Scripps Florida and Scripps Research in La ...FRANCISCO, Calif., and LA JOLLA, Calif., May 14 /P...Inc. (Nasdaq: PARD ), a,biopharmaceutical company...titute, a non-profit biomedical research organizat...ecuted licensing classes of protein kinase,inhibit...
(Date:5/14/2008)...innovations advocate to lead expansion of Cytel,s ... business, CAMBRIDGE, Mass., May 14 /PRNewswire/ ...l design services and specialized statistical soft...inlan as Vice President,Adaptive Trials., Judith...xperience to,the Cytel team. Prior to joining Cyte...
(Date:5/14/2008)...4 /- The Quigley,Corporatio... a study,conducted by its wholly owned subsidiary,...ens to evaluate the anti-viral activity of its com...hicks that had been infected,with Infectious Bronc...ed,that QR448(a) is efficacious against an IBV cha...
(Date:5/13/2008)...PRNewswire-USNewswire/ -- In women at increased,ri...d examination to,routine mammography revealed 28 p...r, the additional ultrasound exam substantially in...nnecessary biopsies, according to an,American Coll...lished in,the May 14, 2008 issue of the Journal of...
Breaking Medicine Technology:Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 4Judith Quinlan Joins Cytel as Vice President, Adaptive Trials 2Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 2Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 3Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 4Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 5Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer 2Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer 3Why do autumn leaves bother to turn red 3F 969 1Why do autumn leaves bother to turn red 3F 969 2Research sheds new light on how diseases jump across species 968 1Research sheds new light on how diseases jump across species 968 2ZONARE Names Marcotte Chief Financial Officer 4588 1ZONARE Names Marcotte Chief Financial Officer 4588 2SafeHands School Program to Help Fight Spread of MRSA Staph Virus 4583 1SafeHands School Program to Help Fight Spread of MRSA Staph Virus 4583 2
...GE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - Combinat...that data from its,randomized, blinded, placebo-co...ients with osteoarthritis (OA) and rheumatoid,arth... against,Rheumatism (EULAR) Annual Congress of Rhe...Spain., Schedule of Events: , -- Satellite Symposi...
...33 reduces esophageal reflux - , Waltham, Mass., J...reported positive results of its randomized, doubl...33 for gastroesophageal,reflux disease (GERD). Th...pt for DDP733 as a treatment for nocturnal GERD,(N...tical,significance over placebo on the primary end...
Other Medicine Technology:Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 2Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 3Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study 2Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study 3
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption.
Lyphochek Tumor Marker Control is a comprehensive, bilevel product designed to assess the performance of various cancer antigen tests, including esoteric tumor markers.
Lyphochek Maternal Serum Control is a trilevel product with analytes at clinically significant levels to monitor maternal serum analysis.
Lyphochek Immunoassay Plus Control provides the clinical laboratory with the most comprehensive control in the world for monitoring immunoassay and therapeutic drug monitoring procedures, eliminating
Medicine Products: